Bulk Manufacturer of Controlled Substances Application: AMPAC Fine Chemicals Virginia, LLC, 32284 [2021-12812]
Download as PDF
<![CDATA[
lotter on DSK11XQN23PROD with NOTICES1
32284
Federal Register / Vol. 86, No. 115 / Thursday, June 17, 2021 / Notices
Blanton, M.D., 43 FR 27,616, 27,617
(1978).
This rule derives from the text of two
provisions of the CSA. First, Congress
defined the term ‘‘practitioner’’ to mean
‘‘a physician . . . or other person
licensed, registered, or otherwise
permitted, by . . . the jurisdiction in
which he practices . . . , to distribute,
dispense, . . . [or] administer . . . a
controlled substance in the course of
professional practice.’’ 21 U.S.C.
802(21). Second, in setting the
requirements for obtaining a
practitioner’s registration, Congress
directed that ‘‘[t]he Attorney General
shall register practitioners . . . if the
applicant is authorized to dispense . . .
controlled substances under the laws of
the State in which he practices.’’ 21
U.S.C. 823(f). Because Congress has
clearly mandated that a practitioner
possess state authority in order to be
deemed a practitioner under the CSA,
the DEA has held repeatedly that
revocation of a practitioner’s registration
is the appropriate sanction whenever he
is no longer authorized to dispense
controlled substances under the laws of
the state in which he practices. See, e.g.,
James L. Hooper, 76 FR at 71,371–72;
Sheran Arden Yeates, M.D., 71 FR
39,130, 39,131 (2006); Dominick A.
Ricci, M.D., 58 FR 51,104, 51,105 (1993);
Bobby Watts, M.D., 53 FR 11,919, 11,920
(1988); Frederick Marsh Blanton, 43 FR
at 27,617.
Under Nebraska law, ‘‘[d]ispense
means to deliver a controlled substance
to an ultimate user or a research subject
pursuant to a medical order issued by a
practitioner authorized to prescribe,
including the packaging, labeling, or
compounding necessary to prepare the
controlled substance for such delivery.’’
Neb. Rev. Stat. § 28–401(8) (Westlaw,
Current through legislation effective
May 6, 2021). Further, ‘‘[p]ractitioner
means a physician . . . or any other
person licensed, registered, or otherwise
permitted to distribute, dispense,
prescribe, conduct research with respect
to, or administer a controlled substance
in the course of practice or research in
this state . . . .’’ Id. at § 28–401(21).
Because Registrant is not currently
licensed as a physician, or otherwise
licensed, in Nebraska, he is not
authorized to dispense controlled
substances in Nebraska.
Here, the undisputed evidence in the
record is that Registrant currently lacks
authority to practice medicine in
Nebraska. As already discussed, a
physician must be a licensed
practitioner to dispense a controlled
substance in Nebraska. Thus, because
Registrant lacks authority to practice
medicine in Nebraska and, therefore, is
VerDate Sep<11>2014
18:41 Jun 16, 2021
Jkt 253001
not authorized to handle controlled
substances in Nebraska, Registrant is not
eligible to maintain a DEA registration.
Accordingly, I will order that
Registrant’s DEA registration be
revoked.
Order
Pursuant to 28 CFR 0.100(b) and the
authority vested in me by 21 U.S.C.
824(a), I hereby revoke DEA Certificate
of Registration No. FK4149882 issued to
Tareq A. Khedir Al-Tiae, M.D. Further,
pursuant to 28 CFR 0.100(b) and the
authority vested in me by 21 U.S.C.
823(f), I hereby deny any pending
application of Tareq A. Khedir Al-Tiae,
M.D., to renew or modify this
registration, as well as any other
pending application of Tareq A. Khedir
Al-Tiae M.D., for additional registration
in Nebraska. This Order is effective July
19, 2021.
D. Christopher Evans,
Acting Administrator.
[FR Doc. 2021–12755 Filed 6–16–21; 8:45 am]
BILLING CODE 4410–09–P
North Normandy Drive, Petersburg,
Virginia 23805–2380, applied to be
registered as a bulk manufacturer of the
following basic class(es) of controlled
substance(s):
Controlled substance
Methylphenidate ...........
Levomethorphan ...........
Levorphanol ..................
Morphine .......................
Thebaine .......................
Noroxymorphone ..........
Tapentadol ....................
Drug
code
1724
9210
9220
9300
9333
9668
9780
Schedule
II
II
II
II
II
II
II
The company plans to bulk
manufacture the listed controlled
substances for the internal use
intermediates or for sale to its
customers. The company plans to
manufacture the above-listed controlled
substances in bulk for distribution to its
customers. No other activities for these
drug codes are authorized for this
registration.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021–12812 Filed 6–16–21; 8:45 am]
DEPARTMENT OF JUSTICE
BILLING CODE P
Drug Enforcement Administration
NATIONAL AERONAUTICS AND
SPACE ADMINISTRATION
[Docket No. DEA–852]
Bulk Manufacturer of Controlled
Substances Application: AMPAC Fine
Chemicals Virginia, LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
Notice of Intent To Grant an Exclusive,
Co-Exclusive or Partially Exclusive
Patent License
National Aeronautics and
Space Administration.
ACTION: Notice of intent to grant
exclusive, co-exclusive or partially
exclusive patent license.
AGENCY:
AMPAC Fine Chemicals
Virginia, LLC. has applied to be
registered as a bulk manufacturer of
basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY
INFORMATION listed below for further
drug information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before August 16, 2021. Such persons
may also file a written request for a
hearing on the application on or before
August 16, 2021.
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.33(a), this
is notice that on May 5, 2021, AMPAC
Fine Chemicals Virginia, LLC., 2820
SUMMARY:
[Notice: (21–035)]
NASA hereby gives notice of
its intent to grant an exclusive, coexclusive or partially exclusive patent
license to practice the inventions
described and claimed in the patents
and/or patent applications listed in
SUPPLEMENTARY INFORMATION below.
DATES: The prospective exclusive, coexclusive or partially exclusive license
may be granted unless NASA receives
written objections including evidence
and argument, no later than July 2, 2021
that establish that the grant of the
license would not be consistent with the
requirements regarding the licensing of
federally owned inventions as set forth
in the Bayh-Dole Act and implementing
regulations. Competing applications
completed and received by NASA no
later than July 2, 2021 will also be
treated as objections to the grant of the
contemplated exclusive, co-exclusive or
SUMMARY:
E:\FR\FM\17JNN1.SGM
17JNN1
]]>Agencies
[Federal Register Volume 86, Number 115 (Thursday, June 17, 2021)]
[Notices]
[Page 32284]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-12812]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-852]
Bulk Manufacturer of Controlled Substances Application: AMPAC
Fine Chemicals Virginia, LLC
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: AMPAC Fine Chemicals Virginia, LLC. has applied to be
registered as a bulk manufacturer of basic class(es) of controlled
substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for
further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before August 16, 2021.
Such persons may also file a written request for a hearing on the
application on or before August 16, 2021.
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this
is notice that on May 5, 2021, AMPAC Fine Chemicals Virginia, LLC.,
2820 North Normandy Drive, Petersburg, Virginia 23805-2380, applied to
be registered as a bulk manufacturer of the following basic class(es)
of controlled substance(s):
------------------------------------------------------------------------
Drug
Controlled substance code Schedule
------------------------------------------------------------------------
Methylphenidate........................ 1724 II
Levomethorphan......................... 9210 II
Levorphanol............................ 9220 II
Morphine............................... 9300 II
Thebaine............................... 9333 II
Noroxymorphone......................... 9668 II
Tapentadol............................. 9780 II
------------------------------------------------------------------------
The company plans to bulk manufacture the listed controlled
substances for the internal use intermediates or for sale to its
customers. The company plans to manufacture the above-listed controlled
substances in bulk for distribution to its customers. No other
activities for these drug codes are authorized for this registration.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2021-12812 Filed 6-16-21; 8:45 am]
BILLING CODE P
